Hutchmed (China)
HCM
14.28
-0.32
-2.19%
Hutchmed (China)
US · HCM
#2639 by market cap
Listed 2016
14.28
-0.32
-2.19%
Live - 5344 symbols - heartbeat 59s ago
· 2026-10-08 04:18
Pre-market
13.95
-2.31%
After-hours
14.28
0.00%
Overnight
14.30
+0.14%
- Market cap
- 2.49B
- P/E (TTM)i
- 178.50
- P/Bi
- 1.98
- EPSi
- 2.60
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on HCM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 57.29% -0.08pp
- Institutions
- 139
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund38.27%
Mutual Fund17.59%
Sovereign Wealth Fund1.01%
Individual/Insider0.97%
Private Company0.26%
Hedge Fund0.15%
Other41.74%
Top holders as of 2026-06-30
Hutchison Whampoa (China) Limited
38.26% · 66.51M sh
China Universal Asset Management Company Ltd.
2.44% · 4.24M sh
Vanguard Capital Management, LLC
2.18% · 3.78M sh
BlackRock
1.42% · 2.46M sh
GF Fund Management Co., Ltd.
1.22% · 2.12M sh
Norges Bank Investment Management
1.01% · 1.75M sh
Penghua Fund Management Co., Ltd.
0.92% · 1.59M sh
Yinhua Fund Management Co., Ltd.
0.86% · 1.50M sh
Schroder Investment Management (Singapore) Ltd.
0.85% · 1.48M sh
Dacheng Fund Management Co., Ltd.
0.79% · 1.37M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
33 filings tracked · 8 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Hutchison Whampoa (China) Limited | -- | 38.26% |
| Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | 0.55% |
| Chig Fung Cheng | Chief Financial Officer | 0.20% |
| Edith Shih | Company Secretary & Non-Executive Director | 0.14% |
| Charles George Rupert Nixon | Group General Counsel | 0.04% |
| Dan Eldar | Non-Executive Director | 0.02% |
| Shu Mok | Independent Non-Executive Director | 0.02% |
| Lorenso Chiu | Deputy Chief Financial Officer | 0.01% |
| Renu Bhatia | Independent Non-Executive Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-19 | Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | Other Derivative Acquisition | +75,140 | -- |
| 2026-05-19 | Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | Other Derivative Acquisition | +132,864 | -- |
| 2026-05-19 | Chig Fung Cheng | Chief Financial Officer | Other Derivative Acquisition | +26,307 | -- |
| 2026-05-19 | Chig Fung Cheng | Chief Financial Officer | Other Derivative Acquisition | +30,157 | -- |
| 2026-05-19 | Charles George Rupert Nixon | Group General Counsel | Other Derivative Acquisition | +7,445 | -- |
| 2026-05-19 | Charles George Rupert Nixon | Group General Counsel | Other Derivative Acquisition | +7,644 | -- |
| 2026-05-19 | Lorenso Chiu | Deputy Chief Financial Officer | Other Derivative Acquisition | +5,176 | -- |
| 2026-05-19 | Lorenso Chiu | Deputy Chief Financial Officer | Other Derivative Acquisition | +8,863 | -- |
| 2026-03-30 | Charles George Rupert Nixon | Group General Counsel | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Lorenso Chiu | Deputy Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-15 | Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-10 | Chig Fung Cheng | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Dan Eldar | Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Edith Shih | Company Secretary & Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Shu Mok | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Renu Bhatia | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:18:46 · For reference only, not investment advice and not tailored to your situation.